Vaxcyte Corporate Presentation

22 22 VAX-24 Preclinical POC Study Supports Potential to Deliver Broader-Spectrum PCV IgG Antibody Titer Comparisons (Current Standard for Approval in Pediatrics) о ❖ Comparable or better immune responses for VAX-24 relative to Prevnar 13 and Pneumovax 23 across common strains. Potential for approval in pediatrics based on non-inferiority relative to standard of care (≥ 50% of IgG titers one month post-boost). IgG Titer 1 × 105 13 Serotypes in Prevnar & Pneumovax 1×104 1 x 103 1x102 1 × 10 1 T T 1 × 10° 3 Note: +/-95% confidence interval. 4 5 6A 6 B 7F 9V ・カレ 0.11ug VAX-24 18C 19A 19F 23F 2 00 N6 11 Serotypes in Pneumovax 10A- 11A - 0.11ug Prevnar 13 1.1ug Pneumovax 23 12F 15B 17F 20. 22F 33F

View entire presentation